Disparities in Uveal Melanoma: Patient Characteristics

Nichols, Erin E.; Richmond, Ann; Daniels, Anthony B.

doi:10.3109/08820538.2016.1154176

Cited by 17 publications

(15 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mean age at diagnosis in this study was 61 years, which is in keeping with other studies that recognise uveal melanoma as increasing in incidence with age [17, 26]. In relation to other published series, there is increasing evidence to support a higher incidence of uveal melanoma in men [17, 26].…”

Section: Discussionsupporting

confidence: 77%

“…In relation to other published series, there is increasing evidence to support a higher incidence of uveal melanoma in men [17, 26]. Damato and Coupland [27] described gender differences in relation to tumour location with a trend towards thicker, posterior tumours in men and involvement of the ciliary body and iris occurring more frequently in females.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Uveal Melanoma in Ireland

et al. 2018

View full text Add to dashboard Cite

Purpose: To report the clinical features and epidemiology of uveal melanoma in Ireland. Methods: This was an observational study of 253 patients with a new diagnosis of uveal melanoma between June 2010 and December 2015. Main outcome measures included demographics, clinical features, age-adjusted incidence, relative survival, overall survival, and distant metastases-free survival. Results: The mean patient age was 61.7 years. Tumour location was choroidal in 82%, ciliochoroidal in 9%, iridociliary in 2%, and iris in 7%. Treatment modalities included brachytherapy (ruthenium-106 and iodine-125 [64%]), enucleation (27%), and proton beam radiation (8%). The mean age-adjusted incidence of uveal melanoma in Ireland from 2010 to 2015 was 9.5 per million of the population (95% confidence interval [CI]: 8.4–10.7). Four-year relative survival was 81.3% (95% CI: 72.8–87.3). Four-year overall survival was 84% (95% CI: 78–90) and 4-year distant metastases-free survival was 79% (95% CI: 73–86). Conclusion: Based on this data, the incidence of uveal melanoma in Ireland is high when compared with other reported incidence rates in Europe and worldwide. Relative and observed survival were in keeping with other reported European survival rates.

show abstract

Section: Discussionsupporting

confidence: 77%

Section: Discussionmentioning

confidence: 99%

Uveal Melanoma in Ireland

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In Asia, it tends to affect younger individuals (45-55 years of age), while in Europe or in the USA, it usually presents at around the age of 60 years. It should be mentioned that uveal melanoma in young individuals has also been related to congenital melanocytic syndromes (ocular melanosis and dysplastic nevus syndrome), with a mean onset age of 16 years and a better short-term prognosis owing to its lesser locoregional aggressiveness (11,12).…”

Section: Risk Factorsmentioning

confidence: 99%

“…For example, in individuals <60 years of age, there is no clear predisposition for any sex and the ratio of affected females to males is 1:1. At more advanced ages, there is a slight predisposition for males, who also exhibit a higher risk of metastasis and therefore, exhibit a higher mortality rate and a worse prognosis (11,13).…”

Section: Risk Factorsmentioning

confidence: 99%

Update on uveal melanoma: Translational research from biology to clinical practice (Review)

et al. 2020

View full text Add to dashboard Cite

Uveal melanoma is the most common type of intraocular cancer with a low mean annual incidence of 5-10 cases per million. Tumours are located in the choroid (90%), ciliary body (6%) or iris (4%) and of 85% are primary tumours. As in cutaneous melanoma, tumours arise in melanocytes; however, the characteristics of uveal melanoma differ, accounting for 3-5% of melanocytic cancers. Among the numerous risk factors are age, sex, genetic and phenotypic predisposition, the work environment and dermatological conditions. Management is usually multidisciplinary, including several specialists such as ophthalmologists, oncologists and maxillofacial surgeons, who participate in the diagnosis, treatment and complex follow-up of these patients, without excluding the management of the immense emotional burden. Clinically, uveal melanoma generates symptoms that depend as much on the affected ocular globe site as on the tumour size. The anatomopathological study of uveal melanoma has recently benefited from developments in molecular biology. In effect, disease classification or staging according to molecular profile is proving useful for the assessment of this type of tumour. Further, the improved knowledge of tumour biology is giving rise to a more targeted approach to diagnosis, prognosis and treatment development; for example, epigenetics driven by microRNAs as a target for disease control. In the present study, the main epidemiological, clinical, physiopathological and molecular features of this disease are reviewed, and the associations among all these factors are discussed. Contents 1. Introduction 2. Risk factors 3. Clinical manifestations 4. Anatomopathological study of uveal melanoma 5. Molecular classification of uveal melanoma: Genes involved 6. Uveal vs. cutaneous melanoma: Similarities and differences 7. Biology of uveal melanoma 8. Blood biomarkers for uveal melanoma 9. Proteomics and metabolomics in uveal melanoma 10. Clinical management of uveal melanoma 11. Conclusions and future directions

show abstract

“…UM is the most common primary intraocular malignancy among adults, and accounts for up to 85% of all cases of OM 4,5. The incidence of UM in the US is 4.9 per million and has remained stable over the last three decades 6.…”

Section: Introductionmentioning

confidence: 99%

Ocular melanoma-when you have seen one, you have not seen them all: a clinical outcome study from the Surveillance, Epidemiology and End Results (SEER) database (1973–2012)

Mahendraraj¹,

Shrestha²,

Lau³

et al. 2017

OPTH

View full text Add to dashboard Cite

BackgroundOcular melanoma (OM) comprises <5% of all melanomas. Uveal melanoma (UM) is the most common subtype of OM, while conjunctival melanoma (CM) is rare and differs significantly from UM. The purpose of this study is to evaluate a large cohort of OM patients to differentiate demographic, pathologic, and clinical factors between these two neoplasms, which may affect treatment and outcomes.MethodsThe Surveillance, Epidemiology, and End Results database (1973–2012) was used to extract demographic and clinical data on 8,165 OM patients (92.1% UM and 7.9% CM).ResultsBoth CM and UM were most prevalent among Caucasian males in the seventh decade of life. UM patients presented more often with localized disease (90.9% vs 81.2, P<0.01). Surgery (42.8%), radiation (43.0%), or combined surgery and radiation (7.0%) were used in the treatment of UM, while CM was treated almost exclusively with surgery (88.7%). Mean overall survival was longer (15.4 vs 14.6 years; P<0.01) and mortality rates were lower in patients (38.8% vs 46.1%; P<0.01) with CM.ConclusionDespite presenting with more advanced disease than UM, CM is associated with an increased overall survival. Surgery is the primary therapy for CM, whereas radiotherapy is the primary therapy for UM and is associated with prolonged survival.

show abstract

Disparities in Uveal Melanoma: Patient Characteristics

Cited by 17 publications

References 65 publications

Uveal Melanoma in Ireland

Uveal Melanoma in Ireland

Update on uveal melanoma: Translational research from biology to clinical practice (Review)

Ocular melanoma-when you have seen one, you have not seen them all: a clinical outcome study from the Surveillance, Epidemiology and End Results (SEER) database (1973–2012)

Contact Info

Product

Resources

About

Disparities in Uveal Melanoma: Patient Characteristics

Cited by 17 publications

References 65 publications

Uveal Melanoma in Ireland

Uveal Melanoma in Ireland

Update on uveal melanoma: Translational research from biology to clinical practice (Review)

Ocular melanoma-when you have seen one, you have not seen them all: a clinical outcome study from the Surveillance, Epidemiology and End Results (SEER) database (1973&ndash;2012)

Contact Info

Product

Resources

About

Ocular melanoma-when you have seen one, you have not seen them all: a clinical outcome study from the Surveillance, Epidemiology and End Results (SEER) database (1973–2012)